KENNETH B. LEE JR - 31 Jan 2023 Form 4 Insider Report for BIOCRYST PHARMACEUTICALS INC (BCRX)

Role
Director
Signature
/s/ Alane P. Barnes, by power of attorney
Issuer symbol
BCRX
Transactions as of
31 Jan 2023
Net transactions value
+$25,650
Form type
4
Filing time
02 Feb 2023, 16:15:21 UTC
Previous filing
21 Jun 2022
Next filing
15 Jun 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction BCRX Common Stock Options Exercise $25,650 +15,000 +40% $1.71 52,118 31 Jan 2023 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction BCRX Automatic Stock Option Grant Options Exercise $0 -15,000 -100% $0.000000* 0 31 Jan 2023 Common Stock 15,000 $1.71 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The reporting person engaged in a non-market, cash exercise and hold transaction with respect to these stock options and the underlying shares. The options were originally granted to the reporting person on May 31, 2013 and would have expired on May 31, 2023. No sales of the issuer's common stock have occurred as part of this transaction.